Valneva (VALN) Projected to Post Quarterly Earnings on Wednesday

Valneva (NASDAQ:VALN) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $55.64 million for the quarter.

Valneva Stock Up 0.3 %

Shares of NASDAQ:VALN opened at $6.81 on Tuesday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock has a market cap of $553.39 million, a P/E ratio of -52.38 and a beta of 1.93. The business’s 50 day moving average is $6.15 and its 200 day moving average is $5.59. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research note on Friday, February 28th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.